 PRINCETON, N.J., May 01, 2021 GLOBE NEWSWIRE -- Oyster Point Pharma, Inc. Nasdaq: OYST, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation of data analyses from its Phase 3 ONSET-2 clinical trial evaluating OC-01 varenicline nasal spray for the treatment of signs and symptoms of dry eye disease at the Association for Research in Vision and Ophthalmology ARVO 2021 Virtual Annual Meeting, being held on May 1-5. 